Is IV more effective than oral ketamine?

Direct head-to-head trials are limited, so we cannot say one route is universally more effective than the other. What we can say is that IV delivers approximately 100 percent of the dose into circulation while oral lozenges deliver roughly 16 to 20 percent due to first-pass liver metabolism, per Clements and colleagues in the Journal of Pharmaceutical Sciences (1982). That difference makes IV dosing more predictable and easier to titrate during a session.

Why is oral ketamine cheaper than IV?

Oral programs typically have lower overhead because they do not require an anesthesia provider in the room, an IV setup, continuous vital-signs monitoring, or a clinical recovery space. The trade-off is more variability in absorption and less ability to adjust the dose in real time if a patient is over- or under-responding.

Can I switch from at-home oral ketamine to IV?

Yes, this is a common transition. Many patients start with at-home oral programs and move to IV when they want a more predictable dose, closer monitoring, or better response. Bring your full history to a consultation, including dosing, frequency, and any side effects, so the clinician can plan an appropriate IV protocol.

What did the FDA actually say about compounded ketamine?

In October 2023, the FDA issued a safety alert about compounded ketamine products dispensed for at-home use. The agency raised concerns about insufficient monitoring, the risks of psychiatric and dissociative side effects without supervision, the potential for misuse, and the absence of FDA review for compounded formulations. The alert did not ban compounded oral ketamine, but it asked patients and clinicians to weigh the risks carefully.

Is intranasal Spravato the same as IV ketamine?

No. Spravato is esketamine, a single isomer of ketamine, delivered as a nasal spray. It is FDA-approved for treatment-resistant depression and major depressive disorder with acute suicidal ideation, and it is given under a REMS program in certified clinics. Racemic IV ketamine is a different molecule by route, dose, and regulatory status, and its psychiatric and pain uses remain off-label.

Oral vs IV Ketamine: Bioavailability, Control, and Safety

Bioavailability, in plain English

Bioavailability is the share of a drug that reaches the bloodstream in active form after you take it. When ketamine goes into a vein, that share is essentially 100 percent. There is no detour. The drug enters circulation directly and begins acting on the brain within seconds. When ketamine is swallowed or held in the mouth as a lozenge, most of it is broken down before it ever reaches the brain. The liver metabolizes a large fraction of an oral dose during what pharmacologists call first-pass metabolism.

The seminal measurement comes from a 1982 study by Clements and colleagues in the Journal of Pharmaceutical Sciences, which pegged oral ketamine bioavailability at roughly 16 to 20 percent. That number has held up across decades of follow-up work. A 2019 clinical review by Andrade in The Journal of Clinical Psychiatry summarized the comparative numbers across routes: IV near 100 percent, intranasal in the 25 to 50 percent range, and oral around 16 to 20 percent. The numbers vary by patient, by formulation, and by whether the lozenge is swallowed or held sublingually, but the order is consistent.

Why does this matter? Because if a 100 mg oral dose puts only 16 mg of active drug into circulation, the dose-response relationship is no longer tidy. Two patients on the same milligram strength can end up with meaningfully different exposures depending on liver enzymes, gut absorption, and how disciplined they are about holding the lozenge.

Why route changes the experience

The route of administration shapes three things at once: how much drug arrives, how fast it arrives, and how predictable the arrival is. IV scores well on all three. The clinician sets a rate, the pump delivers it, and the effect reaches a steady state inside the session. If a patient is over-responding, the rate can be dialed back or paused immediately. If they are under-responding, the rate can be adjusted upward within safe limits.

Oral ketamine, by contrast, has a slow onset and a long, uneven tail. A lozenge takes 20 to 60 minutes to peak, and the curve depends heavily on individual physiology. Once the dose is in, it cannot be pulled back. If a patient has an unexpectedly strong dissociative response at home, the only option is to wait it out.

Intranasal sits between the two. Spravato (esketamine) is a nasal spray, FDA-approved for treatment-resistant depression and major depressive disorder with acute suicidal ideation. Its bioavailability is better than oral but lower than IV, and it is administered under a REMS program in certified clinics with monitoring after each dose. We cover the differences in detail in our piece on ketamine versus Spravato.

IV ketamine: predictable, monitored, fully bioavailable

IV is the route used in the bulk of the published research on ketamine for depression, PTSD, and chronic pain. The reason is practical. When you can deliver 100 percent of the dose at a controlled rate, you can study a defined exposure. The often-cited 0.5 mg/kg over 40 minutes protocol that anchored the modern psychiatric literature is an IV protocol, and it has been replicated across dozens of trials.

IV also brings monitoring as a built-in feature, not an add-on. At Music City Ketamine, every infusion is run with continuous pulse oximetry, blood pressure, and heart rate tracking. Marla Peterson, CRNA, oversees every infusion with anesthesia-level monitoring and is on-site throughout the session. Ketamine is a powerful drug. It deserves that level of attention. You can read more about how we approach this in our safety overview and our explanation of how IV sessions work.

Ketamine is FDA-approved as an anesthetic; its use for depression, anxiety, PTSD, and chronic pain is off-label. We say that out loud because honesty about regulatory status is part of informed consent.

Oral lozenges: convenient, less predictable

Oral compounded ketamine, usually a sublingual or buccal lozenge, expanded rapidly during and after the pandemic through telehealth platforms. The appeal is real. There is no clinic visit, no IV, no driver needed, and the cost per dose is lower. Many patients have found benefit from it, and we are not interested in disparaging those experiences.

What we do want to be clear about is the trade-off. Oral bioavailability is variable. Two doses on two different days can produce noticeably different effects in the same person. Some patients chew or swallow the lozenge prematurely, which drops the bioavailability further because more of the drug routes through the gut and liver. Without monitoring, an unexpectedly strong dissociative episode at home is genuinely scary. Without a clinician in the room, a borderline blood pressure response goes unnoticed.

Compounded oral ketamine is also not FDA-reviewed for safety, efficacy, or quality the way commercial drug products are. Compounding pharmacies operate under a different regulatory framework. That is not inherently wrong, but it means the consumer is leaning on the prescribing telehealth provider to vet the formulation. We expand on this comparison in at-home ketamine versus a clinic and at our IV vs at-home overview.

Intranasal Spravato: the FDA-approved middle ground

Spravato is the only formulation of any ketamine-related compound that is FDA-approved for a psychiatric indication. The FDA approved it for treatment-resistant depression in 2019 and added an indication for major depressive disorder with acute suicidal ideation in 2020. It is administered under a Risk Evaluation and Mitigation Strategy program, which means certified clinics, in-office observation for two hours after the dose, and a structured patient registry.

Spravato uses esketamine, the S-enantiomer of the racemic ketamine molecule. Its intranasal bioavailability falls in the 25 to 50 percent range. It is a different drug by route, dose, and regulatory status from IV racemic ketamine, and patients sometimes respond to one and not the other. Insurance coverage is more accessible for Spravato in many cases, which is a meaningful practical difference.

FDA's stance on compounded ketamine

In October 2023, the FDA issued a safety alert about compounded ketamine products being dispensed for at-home use through telehealth. The alert flagged several concerns: psychiatric and dissociative side effects in unmonitored settings, the risk of misuse and dependence, the absence of FDA review of compounded formulations, and reports of adverse events tied to at-home administration. The agency did not ban compounded oral ketamine. It asked patients and clinicians to weigh the risks more carefully, and it reminded the field that compounded drugs do not undergo the same pre-market review as approved products.

Our read of the alert is straightforward. The FDA is not saying compounded oral ketamine cannot help anyone. It is saying that without a clinician monitoring the dose, the route's variability becomes a safety question rather than a convenience question. We cover the regulatory landscape in more depth in the FDA and ketamine.

How to think about which route fits your situation

There is not a single right answer here. There are honest trade-offs.

If predictability and depth of response matter most, IV gives you full bioavailability and the ability to titrate inside the session. The published evidence base is also largest for IV.
If you have a complex medical history, are on multiple psychiatric medications, or have cardiovascular concerns, the monitoring that comes standard with IV is meaningful. A CRNA in the room is not theater.
If insurance coverage is a hard constraint and you meet the diagnostic criteria, intranasal Spravato is worth a conversation with a prescribing provider.
If cost is the deciding factor and you have a stable home environment, compounded oral programs exist. Read the FDA alert. Ask your prescriber how they handle dose titration and adverse events. Decide with eyes open.

Many patients move between routes over time. We see people who started on at-home oral, did not get the response they hoped for, and came in for IV. We also see people who do well on IV induction and then maintain with a different route under a different provider's care. Route is a tool, not an identity.

At Music City Ketamine, we offer IV. That is a deliberate choice. We picked the route with the most predictable dose and the highest standard of monitoring, and we built the practice around it. IV sessions are $475 each, and we are transparent about cost from the first conversation. Insurance typically does not cover off-label IV ketamine, and we tell patients that before they book.

None of this is about claiming IV is always best. It is about being clear on what each route offers and what it costs, in the broadest sense of cost. Bioavailability is not a marketing number. It is the difference between a dose you can predict and a dose you cannot.